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Background: Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite
50-deoxy-5-fluorouridine (50-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3
along with other p53-dependent genes. Here, we examined whether up-regulation of aquaporin 3 (AQP3) mRNA in
cancer cells treated with 50-DFUR represents a collateral transcriptomic effect of the drug, or conversely, AQP3
participates in the activity of genotoxic agents.
Methods: The role of AQP3 in cell volume increase, cytotoxicity and cell cycle arrest was analyzed using
loss-of-function approaches.
Results: 50-DFUR and gemcitabine, but not cisplatin, stimulated AQP3 expression and cell volume, which was
partially and significantly blocked by knockdown of AQP3. Moreover, AQP3 siRNA significantly blocked other effects
of nucleoside analogs, including G1/S cell cycle arrest, p21 and FAS up-regulation, and cell growth inhibition. Short
incubations with 5-fluorouracil (5-FU) also induced AQP3 expression and increased cell volume, and the inhibition
of AQP3 expression significantly blocked growth inhibition triggered by this drug. To further establish whether
AQP3 induction is related to cell cycle arrest and apoptosis, cells were exposed to long incubations with escalating
doses of 5-FU. AQP3 was highly up-regulated at doses associated with cell cycle arrest, whereas at doses promoting
apoptosis induction of AQP3 mRNA expression was reduced.
Conclusions: Based on the results, we propose that the aquaglyceroporin AQP3 is required for cytotoxic activity of
5’-DFUR and gemcitabine in the breast cancer cell line MCF7 and the colon adenocarcinoma cell line HT29, and is
implicated in cell volume increase and cell cycle arrest.Background
Nucleoside analogs are currently employed in cancer
treatment. These compounds exert cytotoxic effects by
interfering with the uptake and metabolism of their natural
counterparts. They trigger transcriptomic responses pre-
ferentially encompassing up-regulation of a set of genes
implicated in cell cycle regulation and apoptosis along with
other genes of undefined function in cancer chemotherapy
[1-4]. Among these “non-anticipated” genes, we identified
aquaporin 3 (AQP3) [4]. AQP3-related mRNA levels
dramatically increased (8-fold) after treatment of MCF7
breast cancer cells with the capecitabine catabolite,* Correspondence: mpastor@ub.edu
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distribution, and reproduction in any medium50-deoxy-5-fluorouridine (50-DFUR), a direct precursor of
5-fluorouracil (5-FU). Treatment of these cells with the
human Equilibrative Nucleoside Transporter-1 (hENT1)
inhibitor, NBTI, led to significant resistance to 50-DFUR,
which was associated with a marked decrease in AQP3
up-regulation. Thus, it appears that changes in AQP3-
related mRNA levels parallel the cytotoxic effects of
nucleoside derivatives on breast cancer cells.
Aquaporins (AQPs) are integral membrane proteins
implicated in the selective transport of water across the
plasma membrane. A subset of the AQP family that
includes AQP3 also mediates glycerol uptake. Accord-
ingly, these proteins are designated aquaglyceroporins
[5-7]. When AQP3 was initially identified as putative
drug target, limited information was available on the role
of this protein family in cancer. Recent evidence
suggests that selective AQP participate in angiogenesis,
cell migration and metastasis (reviewed by [8]). AQP1-d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ous implantation of melanoma cells, which is associated
with reduced endothelial cell migration and angiogenesis
[9]. Moreover, AQP1 expression promotes tumor cell
extravasation and metastasis [10]. AQP3 has been impli-
cated in skin tumorigenesis. AQP3-null mice are resistant
to the development of skin tumors, while skin squamous
cell carcinomas overexpress this protein [11]. Clinical data
from a number of studies provide evidence for the hetero-
geneous expression of different AQP family members
in solid tumors, and in most cases, AQP overexpression
[12-15].
The possibility that a particular AQP gene member is
implicated in the chemotherapeutic response to antitu-
mor agents has not been addressed. Moreover, previous
studies reporting acute AQP3 up-regulation following
nucleoside-derived drug treatment in cultured cancer
cells do not provide insights into whether changes in the
AQP3-related mRNA level represent a collateral effect
of treatment or, on the contrary, it participates in drug
response, either by promoting it or by acting as a resist-
ance gene. In this study, we address whether AQP3 is
implicated in drug responses by monitoring the effects
of gene silencing on expression patterns of nucleoside
analogs-induced target genes, cell cycle progression, and
cell growth in the breast cancer cell line MCF7 and the
colon adenocarcinoma cell line HT29.
Methods
Reagents
50-DFUR, 5-fluorouracil, cisplatin (cis-diaminedichloro-
platinum or cis-DDP) and propidium iodide were pur-
chased from Sigma-Aldrich (Saint Louis, MO, USA).
Gemcitabine (20,20-difluorodeoxycytidine, dFdC, GemzarW)
was obtained from Eli Lilly and Company (Indianapolis,
IN, USA).
Cell culture and treatments
The human colorectal carcinoma cell line HT29 (HTB-38,
ATCC-LGC Promochem Partnership, USA) and two
human breast carcinomas cell lines, MCF7 (HTB-22,
ATCC-LGC Promochem Partnership, USA) and MDA-
MB-468 (HTB-132, ATCC-LGC Promochem Partnership,
USA) were purchased from the American Type Culture
Collection with the indicated references. MCF7 and
MDA-MB-468 cell lines are characterized by the fact
that the former expresses the estrogen and progesterone
receptors whereas the latter is negative for both. NP-29
cells were derived from human pancreatic adenocar-
cinomas, which had been perpetuated as xenografts in
nude mice and further characterized for different
oncogene and tumor suppressor profiles [16]. MCF7
and HT29 cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetalbovine serum (GIBCO-BRL, Grand Island, NY, USA),
2 mM glutamine, and a mixture of antibiotics (100 U
penicillin, 0.1 mg/ml streptomycin and 0.25 μg/ml fun-
gizone). The MDA-MB-468 cell line was maintained in
DMEM and F12 mixture (1:1) supplemented with 10%
fetal bovine serum, 2 mM glutamine and 100U penicillin,
0.1 mg/ml streptomycin. NP-29 cells were maintained in
DMEM and F12 mixture (1:1) supplemented with 5% fetal
bovine serum, 2 mM glutamine and 100U penicillin,
0.1 mg/ml streptomycin. Cells were maintained as mono-
layer cultures at 37°C in an atmosphere containing 5%
CO2, and subcultured by trypsinization every 4–5 days.
Mycoplasma test assays, verification of morphology and
growth curve analysis were performed as a routine
protocol for all of them. Cells were treated 24 h after
seeding at 20 000 cells/cm2. Cultures were exposed to
drugs for 90 min (50-DFUR: 250 μM; 5-FU: 250 μM;
gemcitabine: 100 nM for MCF7, 250 nM for MDA-MB-
468 and NP-29 and 50 μM for HT29; cisplatin: 50 μM),
and measurements performed at 24 or 48 h after drug
addition. Drug concentrations were chosen based upon
the EC75 values calculated from MTT cell viability
assays, as previously described [4,17]. The choice of
90 min was based upon the need to highlight the role
transport processes play in drug action but, more
importantly, to better mimic the in vivo exposure time
to the drug, which is far less shorter than the “classical”
cytotoxicity assays in which cells are exposed to drugs
for 24, 48, and even 72 hours.
RNA isolation and quantitative RT-PCR
Isolation of mRNA was performed after treatment using
the SV Total RNA Isolation System (Promega Biotech,
Madison, WI, USA), following the manufacturer’s protocol.
Total DNase-treated RNA (1 μg) was used to generate
cDNA using M-MLV Reverse Transcriptase (Promega
Biotech) and random hexamers (Amersham Pharmacia,
Buckinghamshire, UK) for reverse transcription. Quan-
titative real-time PCR was performed with the ABI
PRISM 7700 Sequence Detection System (Applied Bio-
systems, Foster City, CA) using the manufacturer’s recom-
mendations. Assays-on-Demand Taqman probes (Applied
Biosystems) for AQP3, CDKN1A/p21, TNFRSF6/FAS
and GAPDH were employed (Hs00185020_m1, Hs003
55782_m1, Hs00163653_m1 and 4310884E, respect-
ively). Relative quantification of gene expression was
performed as described in the TaqMan user manual
with GAPDH as an internal control.
Measurement of cell volume and cell counting
Cells were plated in 24-well culture plates. After 24 h,
cells were treated for 90 min with different genotoxic
agents. Cultures were allowed to proceed for 48 h. The
cell culture was washed and the remaining cells were
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and number were measured using a cell counter Coulter
Multisizer (Beckman Coulter, Inc., Fullerton, CA) or
Quanta SC flow cytometer (Beckman Coulter). The popu-
lation of viable cells was discriminated by size and the
number of cells was calculated as a percentage by compar-
ing the cell number from treated cultures with that from
cultures not exposed to cytotoxic drugs.
Transfection with small interfering RNA (siRNA) for AQP3
AQP3 siRNA (ID: 147362) was purchased from Ambion
(Austin, TX, USA). SilencerW Negative Control siRNA
#1 (Ambion) was employed as the negative control to
ensure silencing specificity in all the experiments.
Transfection of cells with 20–25 nM (MCF7) or 200 nM
(HT29) of siRNA was performed using Lipofectamine
2000W (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s recommendations. Transfection efficiency
was measured using AQP3 siRNA (ID: 147362) labeled
with FAM (6-carboxy-fluorescein) and a Beckman
Coulter flow cytometer (Fullerton, CA). Depletion of
AQP3 expression following siRNA transfection was
confirmed by real-time RT-PCR, as described above.
Cell cycle analysis
At 48 h after treatment, cells were collected by centrifu-
gation at 1200 g for 4 min and fixed in cold 70% ethanol.
After 24 h, cells were washed and resuspended in 0.5 ml
of PBS containing RNase (10 μg/ml). Flow cytometry
analysis was performed within 1 h after the addition of
propidium iodide (0.1 mg/ml) at room temperature
using a Coulter XL (Beckman Coulter).
Western blot analysis
Cells were lysed in a RIPA buffer containing 1%
Complete Mini protease inhibitors (Roche, Mannheim
Germany). Protein concentration was determined by the
Bradford assay (Bio-Rad, Hercules, CA) and 30 μg of
total protein were resolved by electrophoresis on 12%
SDS-PAGE gels and transferred to PVDF membranes by
standard methods. Membranes were immunoblotted
with anti-p21 (Santa Cruz, Santa Cruz, CA), anti-Fas
(Roche, Mannheim, Germany) and anti-tubulin (Sigma,
St Louis, Mo) and the corresponding secondary anti-
bodies, horseradish peroxidase (HRP)-conjugated anti-
bodies (Bio-Rad, Hercules, CA). Antibody labeling was
detected using the chemiluminiscence detection kit (Bio-
logical Industries, Israel).
Apoptosis detection
Apoptosis was measured using the Annexin V-FITC
Apoptosis Detection Kit I (BD Biosciences, San Diego,
CA). Cells were harvested by centrifugation (including
detached cells) 48 h after treatment with increasingdoses of 5-fluorouracil (5–500 μM), washed twice in
PBS, and pelleted again. They were resuspended at 106
cells/ml in binding buffer, 100 μl of cells were stained
with 5 μl Annexin-V and 5 μl propidium iodide, and
incubated in the dark for 15 min at room temperature,
as recommended by the manufacturer. Following the
addition of 400 μl binding buffer, cells were processed
within 1 h using the FACScan flow cytometer Coulter
XL (Beckman Coulter).
Statistical analysis
The paired or unpaired Student’s t-test was used to com-
pare experimental data. Analysis was performed using
GraphPad Prism software (GraphPad Software, Inc., San
Diego, CA).
Results
Up-regulation of AQP3 expression by genotoxic agents
AQP3 was previously identified as an up-regulated
gene in 50-DFUR-treated MCF7 cells using cDNA
microarray experiments. To further determine whether
up-regulation is specific in response to this particular
agent or additionally induced by other genotoxic drugs
MCF7 cells were exposed for 90 min to 250 μM
50-DFUR, 100 nM gemcitabine or 50 μM cisplatin, and
AQP3 mRNA levels were analyzed by RT-PCR after 24
and 48 h of treatment (Figure 1a). Drug concentrations
were selected based on previously calculated EC75
values using MTT cell viability assays. Both nucleoside-
derived drugs, 50-DFUR and gemcitabine enhanced
AQP3-related mRNA levels at the time-points assayed
(24 and 48 h), albeit at different magnitudes (5-7-fold
by 50-DFUR vs 3-fold by gemcitabine). Interestingly,
the alkylating drug cisplatin did not affect the AQP3
mRNA level.
Since AQP3 functions as a water channel, we deter-
mined whether induction of the gene is associated with
the changes in cell volume after drug treatment.
Accordingly, cellular diameter was measured under dif-
ferent treatment conditions, as shown in Figure 1b.
Consistent with AQP3 mRNA data, 50-DFUR and gem-
citabine, but not cisplatin, induced a significant increase
in cell diameter in MCF7 cells, although in this case,
the magnitude of the effect of gemcitabine was higher
than that of 50-DFUR.
In order to elucidate if this effect could be extended to
other cancer cells, effect of 50-DFUR and gemcitabine
treatment on AQP3 expression and cell volume were
tested in the colon carcinoma cell line HT29, the
pancreatic cancer cell line NP-29 and the ER/PR negative
breast cancer derived MDA-MB-468. Cells were exposed
for 90 min to 50-DFUR or gemcitabine and AQP3 mRNA
levels analyzed by RT-PCR after 48 h of treatment
(Figure 1c). Drug concentrations were selected based on
Figure 1 Effect of genotoxic drugs on AQP3 expression and cell volume. MCF7 (a) or HT29, NP-29 and MDA-MB-468 (c) cells were
incubated for 90 minutes (50-DFUR (DF): 250 μM; gemcitabine (G): 100 nM for MCF7, 250 nM for NP-29 and MDA-MB-468 and 50 μM for HT29;
cisplatin (CP): 50 μM) and mRNA was isolated at 24 (a) or 48 hours (a, c). Real-time RT-PCR analysis for AQP3 was performed using GAPDH as
endogenous control. Data are calculated as arbitrary units relative to untreated cells (CT) as a reference. Results are the mean ± SE of three to six
independent experiments measured in duplicate. At 48 hours after 90 min exposure to the genotoxic drugs, MCF7 (b) or HT29, NP-29 and MDA-
MB-468 (d) cells were collected and volumes were measured as cell diameters (μm). Results are the mean ± SE of three to four independent
experiments measured in triplicate. Statistical significance was assessed with the Student’s t test (* p < 0.05; ** p < 0.01; *** p < 0.001).
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0-DFUR: 250 μM;
gemcitabine: 250 nM for NP-29 and MDA-MB-468 and
50 μM for HT29). Similarly to MCF7, both nucleoside-
derived drugs, 50-DFUR and gemcitabine, enhanced
AQP3-related mRNA levels in HT29 and NP-29 albeit at
different magnitudes, and gemcitabine also induced an
increase in the expression of AQP3 in the MDA-MB-468
cell line. In the same way, the colon cancer cell line HT29
and the pancreatic cancer cell line NP-29 showed an
increase in cell diameter after treatment with both nucleo-
side analog drugs and MDA-MB-468 only exhibited
an increased cell volume after gemcitabine treatment
(Figure 1d).
AQP3 knockdown suppresses the increased cell volume
and cytotoxicity induced by nucleoside analogs
To establish the specific role of AQP3 in cellular
responses to nucleoside-derived drugs, we examined the
effects of inhibiting AQP3 expression using siRNA.
Transfection of cells with AQP3 siRNA resulted in 75%
and 20% reduction in the AQP3-related mRNA levels in
MCF7 and HT29 cells respectively (data not shown).
Transfection efficiency, measured using FAM (6-carboxy-
fluorescein)-labeled AQP3 siRNA was approximately
75% in MCF7 cells and 55% in HT29 cells. Moreover,
AQP3 mRNA silencing lasted for 96 hours sincetransfection, being able to block the up-regulation of
AQP3 expression induced by 50-DFUR treatment (data
not shown).
To assess the putative role of AQP3 in cell volume
regulation in response to genotoxic agents, we measured
changes in the cell diameter after nucleoside analog
treatment in non-transfected, negative control siRNA-
transfected and AQP3 siRNA-transfected cells. Cells
were incubated for 90 min with 50-DFUR or gemcitabine
(50-DFUR: 250 μM; gemcitabine: 100 nM for MCF7 and
50 μM for HT29), and cell diameters measured after
48 h (Figure 2a). As shown previously, both drugs
induced a marked increase in cell diameter. Inhibition of
AQP3 expression significantly reduced but did not fully
prevent the increase in cell volume triggered by the
nucleoside-derived drugs in MCF7 and HT29 cells. Both
nucleosides additionally exerted dramatic effects on cell
viability as determined by measuring the number of cells
after 48 h of treatment (Figure 2b). Similarly to cell vol-
ume changes, AQP3 silencing resulted in significant
reversion of nucleoside-induced cell growth inhibition in
the breast cancer cell line MCF7, and to a lesser extent
in the colon cancer cell line HT29 after treatment with
50-DFUR. However, the cell growth arrest induced by
gemcitabine in HT29 was not blocked by the inhibition
of AQP3 expression.
Figure 2 Effects of AQP3 silencing on cell volume changes and
inhibition of cell growth induced by nucleoside analogs. Non-
transfected (white), negative control siRNA (dashed) or AQP3-siRNA
(black) transfected MCF7 or HT29 cells were treated for 90 min with
250 μM 50-DFUR or 100 nM gemcitabine for MCF7 and 50 μM
gemcitabine for HT29. After 48 hours cells were trypsinized and
diameter was measured as an estimation of volume changes (a)
along with number of cells (b) using a cell counter. Cell viability is
calculated as a percentage basis in relation to untreated cells as a
reference. Results are presented as means ± SE of six independent
experiments measured in triplicate. Statistical significance was
assessed with the paired Student’s t test (* p < 0.05; ** p < 0.01;
*** p < 0.001).
Figure 3 Effects of genotoxic agents on the cell cycle. 48 hours
after 90 min treatment with genotoxic drugs (250 μM 50-DFUR, 100
nM gemcitabine for MCF7 and 50 μM gemcitabine for HT29),
non-transfected (NT), negative control siRNA (NC) or AQP3-siRNA
(siA) transfected MCF7 (a) or HT29 (b) cells were stained with
propidium iodide, and cell cycle was analyzed with a flow
cytometer. Results are presented as means of four to six
independent experiments. Statistical significance was assessed
with the Student’s t test (* p < 0.05; ** p < 0.01).
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blocking the activity of AQP3 with CuSO4 in MCF7 cells
(data not shown). Copper salts are effective AQP3 inhibi-
tors [18,19] but also can display toxicity, and independ-
ently exert a variety of effects on cell responses to DNA
damage. Thus, inhibition of AQP3 activity supports the
data obtained when silencing AQP3 expression.
AQP3 silencing partially reverses cell cycle arrest
triggered by nucleoside-derived drugs and up-regulation
of transcriptional targets
Treatment of cells with 50-DFUR and gemcitabine
induced cell cycle arrest at the G1-S phase in MCF7 cells
(Figure 3a), whereas cisplatin promoted accumulation of
cells at the S-G2 phase (data not shown), fact that had
previously been reported [20]. Interestingly, AQP3
siRNA significantly blocked cell cycle arrest induced by
both nucleoside-analogs in MCF7 cells (Figure 3a).Similarly to the reversion of cell growth inhibition in
HT29 cell line (Figure 2b), only the cell cycle arrest trig-
gered by 50-DFUR was reversed, but not the one trig-
gered by gemcitabine (Figure 3b). To eliminate the
possibility that cell cycle-dependent regulation of AQP3
expression interferes with these phenomena, MCF7 cells
were synchronized by serum depletion, and AQP3-
related mRNA levels analyzed during cell cycle progres-
sion. Under these conditions, we observed no differences
in AQP3 mRNA levels (data not shown).
50-DFUR and gemcitabine up-regulate a variety of
genes, generally in a p53-dependent manner [4,17]. We
analyzed whether AQP3 knockdown affects the tran-
scriptional response associated with drug treatment in
MCF7, cell line in which we observed the clearest effects
on cell cycle. Non-transfected, negative control siRNA-
transfected or AQP3 siRNA-transfected cells were incu-
bated for 90 min with either 50-DFUR or gemcitabine,
and p21 and Fas expression analyzed after 24 h at the
mRNA level using real-time PCR (Figure 4a and 4b) or
at the protein level by western blot (Figure 4c). Inhib-
ition of AQP3 expression led to partial blockage of the
increase in p21 and Fas mRNA levels induced by
Figure 4 Inhibition of transcriptional targets of 5’-DFUR and
gemcitabine by AQP3-siRNA. Non-transfected (white), negative
control siRNA (dashed) or AQP3-siRNA (black) transfected MCF7 cells
were incubated for 90 minutes with 250 μM 5’-DFUR or 100 nM
gemcitabine. After 24 h, RNA was isolated and real-time RT-PCR
analysis for p21 and Fas performed (a and b, respectively). CT values
for each gene are normalized to an endogenous reference gene
(GAPDH). mRNA levels are calculated in arbitrary units using control
values as the reference. Results are presented as means ± SE of four
to six independent experiments measured in duplicate. Statistical
significance was assessed with the Student’s t test (* p< 0.05;
** p< 0.01). (c) Non-transfected or AQP3-siRNA transfected MCF7 cells
were treated for 90 minutes with 250 μM 5’-DFUR or 100 nM
gemcitabine and Western blot analysis was perfomed for p21, Fas and
α-tubulin as a loading control. A representative Western blot is shown.
Figure 5 Effect of 5-fluorouracil on AQP3 expression (a) and
cell volume (b) and effect of AQP3 silencing on cell growth
inhibition induced by 5-fluorouracil (c). MCF7 cells were
incubated for 90 minutes with 5-FU (FU) 250 μM and mRNA was
isolated at 48 hours (a). Real-time RT-PCR analysis for AQP3 was
performed using GAPDH as endogenous control. Data are calculated
as arbitrary units relative to untreated cells (CT) as a reference.
Results are the mean ± SE of three independent experiments
measured in duplicate. At 48 hours after 90 min exposure to 250 μM
5-FU, MCF7 cells (b) were collected and volumes were measured as
cell diameters (μm). Results are the mean ± SE of three independent
experiments measured in triplicate. (c) Non-transfected (white),
negative control siRNA (dashed) or AQP3-siRNA (black) transfected
MCF7 were treated for 90 min with increasing doses of 5-FU
(5 to 500 μM). After 48 h cells were trypsinized and the number of
cells was measured using a cell counter. Cell viability is calculated as
a percentage in relation to untreated cells as a reference. Results are
the mean ± SE of three independent experiments measured in
triplicate. Statistical significance was assessed with the Student’s t
test (* p < 0.05; ** p < 0.01; *** p < 0.001).
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and 4b, respectively). AQP3 siRNA-mediated blockage
of the increase in p21 and Fas after treatment with
50-DFUR was also confirmed at the protein level
(Figure 4c). However, gemcitabine treatment led only to
an increase in p21 protein levels, which was reversed
by the AQP3 knock-down (Figure 4c).In terms of previous parameters (cell volume and
drug-induced toxicity), similar results were obtained at
24 h upon inhibition of AQP3 activity using CuSO4
(data not shown).
AQP3 silencing reverses cytotoxicity induced by
5-fluorouracil
50-DFUR is the immediate precursor of the active fluoro-
pyrimidine 5-fluorouracil (5-FU). To further evaluate if
the effects described for 50-DFUR could also be extended
to 5-FU, MCF7 cells were incubated for 90 min with
250 μM 5-FU and AQP3 mRNA levels and cell volume
were analyzed. Similarly to 50-DFUR effects, AQP3 mRNA
expression (Figure 5a) and cell volume (Figure 5b) were
increased after 90 min treatment with 5-FU. To analyze
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experiments in which non-transfected, negative control
siRNA-transfected or AQP3 siRNA-transfected cells were
treated with different doses of 5FU for 90 min and cell
number measured after 48 h. As shown in Figure 5c,
escalating doses of 5FU induced a progressive decrease in
cell number, which was fully reversed at low 5-FU concen-
trations (5 μM) or partially but significantly reversed at
higher 5-FU concentrations (up to 500 μM) when AQP3
expression was silenced.
Induction of apoptosis by 5-fluorouracil suppresses the
increase in AQP3 expression in MCF7 cells
Under our experimental conditions, 90-minute treat-
ment with either 50-DFUR or 5-FU led to arrest of cell
cycle progression at 48 h, but did not ultimately pro-
mote apoptosis. Interestingly, longer incubations (48 h)
with 5-FU but not with 50-DFUR were able to induce
some apoptosis in MCF7 cells. For this reason, long
incubations of increasing concentrations of 5-FU were used
to further determine whether AQP3 induced by nucleoside
analogs plays a role in cell cycle arrest and/or death.Figure 6 Effects of 5-FU on apoptosis (a), cell cycle (b), and Fas, p21 a
doses of 5-FU for 48 hours (a) Apoptosis was quantified by double staining
analyzed with a FACScan flow cytometer. (b) The DNA content was measu
sorting analysis. (c) Real-time RT-PCR for each gene was performed, after RN
levels are presented as arbitrary units in relation to control values as the re
measured in triplicate, three independent experiments were performed.MCF7 cells were treated with increasing doses of
5-FU, and the cell cycle and apoptosis analyzed at 48 h
(Figure 6a,b). Treatment with low doses of 5-FU (5, 25 or
75 μM) led to cell cycle arrest at the G1-S phase, but not
significant cell death. Conversely, upon incubation of cells
with 5-FU at high concentrations (250 or 500 μM),
increased apoptosis was observed (20-30%) whereas the
cell cycle was poorly affected.
The mRNA levels of Fas, p21 and AQP3 were mea-
sured under the above conditions (Figure 6c). The peak
of FAS-related mRNA levels was achieved at the highest
doses of 5-FU, which do not affect cell cycle progression
but strongly promote apoptosis. On the other hand,
p21-related mRNA amounts linearly increased with
5-FU doses at the lower concentration range (5–75 μM),
but were less affected at the highest 5-FU concentration
(500 μM). Interestingly, AQP3 expression was dramatic-
ally increased at doses associated with cell cycle arrest (5,
25 or 75 μM), whereas upon escalating to concentrations
reported to promote apoptosis (250 or 500 μM), the
increase in AQP3-related mRNA levels was even reduced,
down to near basal levels at 500 μM 5-FU.nd AQP3 mRNA levels (c). Cells were incubated with increasing
with Annexin-V conjugated to FITC and propidium iodide, and
red using propidium iodide staining and fluorescence-activated cell
A isolation using GAPDH as the internal control. mRNA expression
ference. Results are the mean ± SE of a representative experiment
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High-throughput transcriptomic analysis of anticancer
drug activity is a suitable tool to identify novel target
genes. However, confirmation that a particular drug-
modulated gene specifically contributes to drug response
requires detailed analysis similar to that performed for
AQP3, a gene up-regulated by the 5-FU precursor and
capecitabine catabolite, 50-DFUR, in the breast cancer
cell line MCF7 [4].
AQP3 is a broadly expressed aquaglyceroporin found
in most epithelia, where it localizes to the basolateral
membrane, as well as in several types of nonepithelial
cells [21]. The extensive distribution pattern suggests
that this water channel protein is a major player in
barrier hydration and water and osmolyte homeostasis.
AQP3 is a target of aldosterone in the collecting duct
[22] and under osmotic control in renal and keratocar-
cinoma cells, thus presumably contributing to cell
volume adaptive regulatory processes [23,24]. While
previous studies suggest that changes in cell size asso-
ciated with cell division are facilitated by increased
AQP1 abundance at the plasma membrane [25], our
results support a putative role of AQP3 in maintaining
or promoting cell swelling induced by nucleoside-
derived drugs. Interestingly, AQP3-related mRNA levels
were not modified during cell cycle progression, sug-
gesting that the role of the water channel in the
increased cell volume is related to drug response. The
nucleoside analogs 50-DFUR and gemcitabine triggered
G1/S cell cycle arrest, but not cisplatin. This DNA alkyl-
ating agent appeared to induce S/G2 arrest, which did
not result in increased cell volume, in contrast to the
effects of nucleoside-derived drugs.
Knockdown of AQP3 expression produced a partial
but significant reversion of increased cell swelling asso-
ciated with nucleoside-derived drug treatment, further
supporting a role of AQP3 in this process. Nevertheless,
the magnitude of cell volume reversion in MCF7 and
HT29 (about 25%), even assuming that AQP3 expression
is only partially blocked in siRNA-transfected cells,
suggests that this water channel protein is not the only
contributor to cell swelling associated with drug treatment.
Interestingly, under similar conditions, suppression of
AQP3 preserved cell growth inhibition to a better extent,
and the magnitude of reversion of G1/S cell cycle arrest
was significantly higher than reversion of cell swelling for
50-DFUR and gemcitabine in MCF7 cells. Furthermore, in
spite of achieving only a 20% of AQP3 mRNA knockdown
in HT29, AQP3 suppression partially reverted cell cycle
arrest and preserved cell growth inhibition in 50-DFUR
treated cells. Thus, it is possible that AQP3 plays roles
other than those derived from its ability to mediate water
transport. In fact, AQP3 plays a variety of roles in cell
physiology associated with its ability to take up glycerol.AQP3-deficient mice show defective skin hydration and
elasticity, which can be corrected by glycerol replacement
[26]. Moreover, wound healing is significantly impaired in
these animals, with low keratinocyte proliferation, a fea-
ture that can also be reversed in vivo by feeding mice with
glycerol [27]. Interestingly, inhibition of AQP3 in keratino-
cyte cell cultures results in reduced water and glycerol
permeability and impaired cell migration. The protein
facilitates migration by functioning as a water channel, but
is also implicated in epidermal cell proliferation as a
glycerol transporter [27]. Consistent with this finding,
mice lacking AQP3 expression not only display impaired
epidermal cell proliferation but are also resistant to skin
tumorigenesis [11]. This appears to be related to the ability
of AQP3 to take up glycerol, a suitable energy substrate
that supports cell growth. Nucleoside-derived drugs, par-
ticularly those used in antiviral therapy, may induce severe
mitochondrial toxicity [28,29]. While this is not evident
for nucleosides used in the treatment of solid tumors,
recent evidence suggests that gemcitabine triggers moderate
mitochondrial toxicity [30] and blocks the activity of
human mitochondrial DNA polymerase [31]. Nucleo-
side derivatives additionally compete with intracellular
nucleotides and inhibit key enzymes of the nucleoside
salvage pathways [32,33], consequently impairing the
cellular energy metabolism. In this context, it is feasible
to assume that AQP3 induced after exposure to these
drugs plays a compensatory role as a provider of energy
substrates.
AQP3 silencing also reversed the up-regulation of
selective p53-dependent transcriptional targets, such as
the death receptor, FAS, implicated in apoptosis, and the
inhibitor of the cyclin-CDK2 and -CDK4 complexes,
p21, implicated in the modulation of cell cycle progres-
sion at G1. It is not clear from these observations
whether AQP3 contributes to apoptosis in addition to
its reported effect on cell cycle arrest, which is signifi-
cantly reversed upon silencing of the gene. Interestingly,
AQP3 itself is transcriptionally regulated by p73, a mem-
ber of the p53 family, which exhibits similar biochemical
properties but is rarely mutated in cancer cells [34]. p73
interacts with the transcriptional coactivator, Yes-
associated protein (YAP), leading to enhanced p73-
dependent apoptosis in response to DNA damage. YAP
is stabilized by the product of the p73/YAP target gene,
PML, under negative control by the proto-oncogenic
AKT/PKB kinase [35]. Interestingly, the anticancer drug,
curcumin, down-regulates AQP3 expression in cancer
ovarian cells via a mechanism that involves, at least par-
tially, inhibition of the EGFR pathway and downstream
AKT [19]. While AQP3 is a p73 target, its association
with pro-apoptotic processes does not appear relevant,
at least under the conditions used here. This hypothesis
is based on evidence that AQP3 up-regulation is
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cycle arrest, but not at higher doses in which cells are
committed to programmed cell death. Moreover, the
decrease in cell growth associated with short treatment
with low doses of 5-FU is significantly reversed by
knockdown of AQP3 expression. These observations
collectively support the view that induction of this aqua-
glyceroporin is related to cell cycle arrest rather than
apoptosis.
Aquaporins, including AQP3, are overexpressed in dif-
ferent tumors [12,13,15] and an oncogenic role was
suggested for AQP5, although this protein is not an
aquaglyceroporin [13,36]. To our knowledge, no correl-
ation of basal or drug-induced AQP3 expression with
drug chemoresistance has been reported to date. In view
of the above findings, this issue deserves further
investigation.Conclusions
In this contribution we addressed whether up-regulation
of AQP3 following treatment with nucleoside-derived
drugs, such as 50DFUR and gemcitabine, is related to
drug response. Experiments on MCF7 and HT29 cells
with suppressed AQP3 expression confirm that this
aquaglyceroporin is involved in the increase in cell
volume following drug treatment and drug-induced cell
cycle arrest. Thus, AQP3 up-regulation is not a collateral
effect of nucleoside-derived drug action, but may be
implicated in the ability of some cancer cells to respond
to treatment.
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